Sign in

CIK 0001649094

  • Large accelerated filer

Vaxcyte, Inc.

Sign in to watch
Ticker
PCVX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464233385
Phone
+1 650-837-0111
Business address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
Former names
SutroVax, Inc.
  1. 4 Grant or award Director acquired 3,125 shares (grant or award)
  2. 4 Grant or award Director acquired 3,125 shares (grant or award)
  3. 4 Grant or award Director acquired 3,125 shares (grant or award)
  4. 4 Grant or award Director acquired 3,125 shares (grant or award)
  5. 4 Grant or award Director acquired 3,125 shares (grant or award)
  6. 4 Open-market sale SVP Process Dev, Manufacturing sold 3,000 shares at $26.22 ($78,671)
  7. 4 Open-market sale VP, Research sold 4,112 shares at $25.50 ($104,856)
  8. 4 Open-market sale President and CFO sold 3,100 shares at an average $24.44 ($75,763)
  9. 4 Open-market sale Chief Executive Officer sold 11,000 shares at an average $23.91 ($262,990)
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market sale VP, Research sold 888 shares at $25.80 ($22,914)
  12. 4 Open-market sale SVP Process Dev, Manufacturing sold 3,000 shares at $25.00 ($75,000)
  13. 4 Open-market sale Chief Operating Officer sold 2,800 shares at $23.98 ($67,130)
  14. 4 Open-market sale President and CFO sold 3,100 shares at $24.05 ($74,542)
  15. 4 Open-market sale Chief Executive Officer sold 11,000 shares at $23.98 ($263,766)
  16. 3 Insider Initial Statement of Ownership
  17. 4 Open-market sale VP, Research sold 5,000 shares at $25.59 ($127,950)
  18. 4 Open-market sale SVP Process Dev, Manufacturing sold 3,000 shares at $25.00 ($75,000)
  19. 4 Open-market sale Chief Executive Officer sold 22,000 shares at an average $24.82 ($546,143)
  20. 4 Open-market sale President and CFO sold 3,100 shares at $26.13 ($80,993)

Page 15 of 22 · 421 filings